Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base
Abstract
BACKGROUND: The optimal treatment for resected pancreatic cancer is controversial because direct comparisons of adjuvant chemotherapy (CT) alone and chemotherapy and radiotherapy (CRT) are limited. This study assessed outcomes of CT versus CRT in a national cohort to provide a modern estimate of comparative effectiveness.METHODS: Patients with pT1‐3N0‐1M0 pancreatic adenocarcinoma after pancreatectomy were identified in the National Cancer Data Base. Overall survival (OS) was compared for CT and CRT groups with Cox regression and propensity score matching. Subset analyses by clinicopathologic characteristics were performed.RESULTS: This study identified 6165 patients treated with CT (n = 2334 or 38%) or CRT (n = 3831 or 62%). Most were classified as pT3 (72%), pN1 (67%), and status‐post R0 resection (84%). For CRT patients, the median radiotherapy dose was 50.4 Gy. Compared with CT, CRT was associated with improved OS in a univariate analysis (median, 20.0 vs 22.3 months; at 5 years, 16.5% vs 19.6%; P < .001) and a multivariate analysis (hazard ratio [HR], 0.893; 95% confidence interval [CI], 0.837‐0.953; P = .001). CRT remained associated with improved OS after propensity score matching (HR, 0.851; 95% CI, 0.793‐0.913; P < .001). Subset analyses showed that CRT was associated with improved OS among patients with pT3 (HR, 0.892; 95% CI, 0.828‐0.962; P = .003) or pN1 disease (HR, 0.856; 95% CI, 0.793‐0.924; P < .001) and both R0 resection (HR, 0.901; 95% CI, 0.839‐0.969; P = .005) and R1 resection (HR, 0.842; 95% CI, 0.722‐0.983; P = .030).CONCLUSIONS: CRT was independently associated with improved OS after the resection of pancreatic adenocarcinoma in a large national cohort and particularly among patients with R1 resection and pN1 disease. Well‐designed randomized comparisons of CRT and CT are urgently needed. Cancer 2015;121:4141–4149. © 2015 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- Impact of Adjuvant Radiotherapy on Survival after Pancreatic Cancer Resection: An Appraisal of Data from the National Cancer Data BaseAnnals of Surgical Oncology, 2013
- Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Failure to Adhere to Protocol Specified Radiation Therapy Guidelines Was Associated With Decreased Survival in RTOG 9704—A Phase III Trial of Adjuvant Chemotherapy and Chemoradiotherapy for Patients With Resected Adenocarcinoma of the PancreasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Analysis of Local Control in Patients Receiving IMRT for Resected Pancreatic CancersInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II StudyJournal of Clinical Oncology, 2010
- Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative StudyAnnals of Surgical Oncology, 2010
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- Chemotherapy for Pancreatic CancerNew England Journal of Medicine, 2004
- Resection Margins in Carcinoma of the Head of the PancreasAnnals of Surgery, 1993